Similar articles

• Guideline for anti-TNF-alpha therapy in psoriatic arthritis.

  Kyle S, Chandler D, Griffiths CE, Helliwell P, Lewis J, McInnes I, Oliver S, Symmons D, McHugh N; British Society for Rheumatology Standards Guidelines Audit Working Group (SGAWG). Kyle S, et al. Rheumatology (Oxford). 2005 Mar;44(3):390-7. doi: 10.1093/rheumatology/keh514. Epub 2005 Feb 3. Rheumatology (Oxford). 2005. PMID: 15695305 Review. No abstract available.
• Genital HPV lesions and molluscum contagiosum occurring in patients receiving anti-TNF-alpha therapy.

  Antoniou C, Kosmadaki MG, Stratigos AJ, Katsambas AD. Antoniou C, et al. Dermatology. 2008;216(4):364-5. doi: 10.1159/000117709. Epub 2008 Feb 20. Dermatology. 2008. PMID: 18285688 No abstract available.
• [Psoriasis and psoriatic rheumatism: effectiveness of etanercept for cutaneous and joint lesions].

  Paul C, Solignac M. Paul C, et al. Ann Dermatol Venereol. 2010 Apr;137(4 Suppl):13-5. doi: 10.1016/S0151-9638(10)70012-0. Ann Dermatol Venereol. 2010. PMID: 20510165 Clinical Trial. French. No abstract available.
• [Recommendations for the appropriate use of anti-TNFalpha therapy in patients with psoriatic arthritis. Italian Rheumatology Society].

  Salvarani C, Olivieri I, Cantini F, Marchesoni A, Punzi L, Scarpa R, Matucci-Cerinic M. Salvarani C, et al. Reumatismo. 2004 Jul-Sep;56(3):133-4, 136-8. Reumatismo. 2004. PMID: 15470517 Italian. No abstract available.
• The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach.

  Gordon KB, Ruderman EM. Gordon KB, et al. J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S85-91. doi: 10.1016/j.jaad.2005.10.052. J Am Acad Dermatol. 2006. PMID: 16488334 Review.